Find Academic Supervisors

Carlos Salomon Gallo is a Professor and NHMRC Investigator Fellow (EL2) at The University of Queensland's Centre for Clinical Research, affiliated with the School of Biomedical Sciences. He directs the Centre for Extracellular Vesicle Nanomedicine and leads the Exosome Biology Laboratory. A globally recognized key opinion leader in extracellular vesicles (ranked 3rd worldwide by Expertscape), his research focuses on EV biology for diagnostic and therapeutic applications in ovarian cancer, gestational diabetes, preeclampsia, and other obstetrical syndromes. His research integrates proteomics (SWATH-MS), miRNA analysis, and advanced isolation techniques to develop liquid biopsies. Core interests include: EV biomarker discovery and validation for early disease detection. Mechanisms of EV-mediated signaling in metabolic and oncological pathologies. Engineering EVs for targeted drug delivery and CRISPR-Cas therapeutics. Clinical translation of EV-based diagnostics (IVDs) and therapeutics. Analysis of his recent articles reveals a dominant focus on EV profiling in pregnancy complications (gestational diabetes, preeclampsia) and oncology (ovarian cancer), utilizing multi-omics approaches. Key trends include developing high-sensitivity EV biosensors, understanding hypoxia-induced EV signaling, and exploring 3D models for EV research. He has received significant recognition, including: NHMRC Emerging Leadership Fellow NHMRC Investigator Fellow (EL2) He leads the Exosome Biology Laboratory and the UQ Centre for Extracellular Vesicle Nanomedicine, fostering cross-disciplinary collaboration. His work involves extensive national and international partnerships, evidenced by leadership roles in the Centre for Clinical Diagnostics and over 20 invited international talks in 5 years. He actively mentors HDR students and contributes to global EV research standards (MISEV2023).

• Extracellular Vesicles
• Biomarker Discovery
• Exosome Biology
• +7 more

Pengyi Yang is an Associate Professor and University of Sydney Robinson Fellow at the School of Mathematics & Statistics, University of Sydney. He leads the Computational Systems Biology group at the Charles Perkins Centre and holds a conjoint appointment as Unit Head of Computational Systems Biology at the Children's Medical Research Institute (CMRI). His research focuses on computational approaches to understand trans-regulatory networks in stem cells and their applications in regenerative medicine. Yang holds a Ph.D. and has been recognized with awards such as the National Stem Cell Foundation Metcalf Prize (2021). His research spans computational systems biology, machine learning for bioinformatics, and spatial/single-cell omics analysis. Key projects include modeling pluripotency transitions, developing stem cell-derived organoids, and creating computational tools for phosphoproteomics and multi-omics integration. Collaborations include international initiatives like the Laboratory of Data Discovery for Health (InnoHK). Yang advises multiple PhD students and leads grants on topics like stem cell-derived brain organoids and embryonic development modeling. His lab develops tools like Cepo, PhosR, and CiteFuse for omics data analysis. He teaches data science and molecular systems biology at the University of Sydney.

• Computational Systems Biology
• Stem Cell Biology
• Bioinformatics
• +4 more

Christina Gertrude Yap is a Senior Lecturer in Metabolic Medicine at the Jeffrey Cheah School of Medicine and Health Sciences (JCSMHS), Monash University Malaysia. She is actively involved in research, teaching, and academic leadership, with a focus on diabetic nephropathy, metabolic disorders, and medical education. She supervises PhD students and leads multiple research projects in diabetes and obesity. PhD in Biomedical Sciences, Monash University (2012) Graduate Certificate in Higher Education, Monash University (2015) Dr. Yap's research centers on identifying early biomarkers for metabolic syndromes, particularly diabetic nephropathy, with a focus on CYP2E1 and other endogenous molecules. Her work integrates proteomics, metabolomics, and animal models to explore pharmacokinetics, xenobiotic interactions, and translational applications. She also investigates teaching and learning methodologies in medical education. Her recent publications (2021–2025) span diabetes, neuroprotection, obesity, and public health, with a strong emphasis on mechanistic studies and clinical translation. Articles explore hippocampal neuroprotection in diabetic rats, social determinants of obesity, and vaccine mechanisms, reflecting a multidisciplinary approach bridging basic science and public health. Scientific awards include: Best Mention Award, 14th Biological Science Congress (2009) Best Presentation Award, 5th World Congress on Diabetes and Metabolism (2014) First Prize and Best Presentation Award, Monash CSJB Research Week and World Congress on Clinical Trials in Diabetes (2017) Seed Grant Award, Monash University (2024) Dr. Yap has been a PhD supervisor since 2011 and is currently accepting new students. She has secured multiple research grants, including active projects on renal protection in type 2 diabetes and anti-obesity effects of natural compounds. Her leadership roles include coordinating physiology and hematology in the MBBS program and serving on the Student Support Committee. She is a member of the Malaysian Scientific Association and the Malaysian Society of Pharmacology & Physiology. She leads a research team focused on metabolic medicine, utilizing advanced analytical techniques and collaborative networks to advance understanding of diabetes and obesity. Her lab integrates molecular biology, animal models, and clinical data to develop early diagnostic tools and therapeutic strategies.

• Diabetic Nephropathy
• Metabolic Syndrome
• Obesity
• +11 more

Dr Stewart Masson is a Research Fellow at the Charles Perkins Centre, University of Sydney, within the Faculty of Science. His research focuses on the genetics of metabolic disease and insulin resistance, with a particular interest in the etiology of insulin resistance and intracellular trafficking mechanisms. He holds a PhD from the University of Auckland (2021), where he studied insulin signaling and β-catenin's role in skeletal muscle glucose transport under Prof. Peter Shepherd and Assoc. Prof. Troy Merry. His work now investigates genetic influences on metabolic health and aging in collaboration with Prof. David James' lab. Research Interests: Genetic determinants of metabolic disorders Insulin resistance mechanisms Cellular trafficking in metabolism Genetic diversity in metabolic responses Publications highlight advancements in understanding insulin signaling pathways, lipid metabolism, and the development of tools like Synteny for gene prioritization. His studies leverage mouse models to explore diet-related metabolic changes and identify therapeutic targets. Advising and Grants: While no students are listed, his research has been supported by projects investigating genetic and dietary influences on metabolic health. Collaborative efforts with the James Lab focus on metabolic cybernetics and systems biology approaches. Labs/Teams: Active member of the James Lab at the Charles Perkins Centre, contributing to the Metabolic Cybernetics research group.

• Metabolic Disease Genetics
• Insulin Resistance
• Cellular Trafficking Mechanisms
• +3 more

Dr. Evelyn Parr is a Senior Research Fellow at the Mary MacKillop Institute for Health Research, Australian Catholic University (ACU), where she conducts translational research in the Exercise and Nutrition Research Program. Her work focuses on the interplay between exercise, nutrition, and metabolic health, particularly in the context of obesity, type 2 diabetes, and body composition. Her educational background includes undergraduate degrees in Physical Education and Science from the University of Otago, New Zealand, followed by a Master’s in Exercise Metabolism and a PhD titled 'Exercise and nutrient interactions: Effects on skeletal muscle and body fat mass,' awarded in 2016 from ACU. Dr. Parr's research centers on time-restricted eating, nutrient timing, and exercise prescription to improve glycemic control and prevent muscle loss, especially in aging and overweight populations. She investigates how manipulating the timing of food intake and physical activity can optimize metabolic outcomes. Her work often involves randomized controlled trials and collaborations with leading institutions like La Trobe University and the University of Adelaide. The recent publication trends highlight a strong focus on time-restricted eating, circadian metabolism, and exercise timing. Her studies integrate nutrition, physiology, and clinical outcomes, contributing to the growing field of chrononutrition and metabolic disease prevention. Best paper of 2020, Exercise and Sports Science Reviews (awarded 2021) International Travel Award, European Association for the Study of Diabetes (EASD) Conference (2019) Australian Postgraduate Award Scholarship (2014–2015) Best student presentation, SESNZ conference (2014) ESPEN Early Career Fellowship (2018–2019) Dr. Parr has secured significant research funding, including an NHMRC Medical Research Future Fund grant for the TREAT study on preventing type 2 diabetes through time-restricted eating. She supervises higher degree research students and collaborates extensively with Prof John Hawley, Dr Brooke Devlin, and A/Prof Leah Brennan. Her editorial roles include Topic Editor for Nutrients and reviewer for top journals such as Diabetologia , Obesity , and Medicine and Science in Sports and Exercise . She is an active member of professional organizations including Exercise and Sports Science Australia (ESSA), ESPEN, EASD, and The Obesity Society, and contributes to grant review panels for Diabetes Australia and NHMRC.

• Exercise Physiology
• Nutrition
• Metabolism
• +7 more

Tony Tiganis is a Professor in the Department of Biochemistry and Molecular Biology at Monash University, where he also serves as Laboratory Head and leads the Metabolism, Diabetes and Obesity Program at the Monash Biomedicine Discovery Institute. He holds a joint appointment as Laboratory Head at the Peter MacCallum Cancer Centre and is an Adjunct Professor at Yale School of Medicine. His multidisciplinary research focuses on protein-tyrosine-phosphatases (PTPs) and their roles in metabolism, cancer, and immunity. Ph.D. in Biochemistry, University of Melbourne (1990–1994) B.Sc. (Hons) in Pharmacology, University of Melbourne (1986–1989) Professor Tiganis’s research centers on tyrosine-phosphorylation-dependent signaling, with a focus on PTPs. His work has challenged long-standing misconceptions about PTPs being 'undruggable' and has revealed their critical roles in obesity, type 2 diabetes, cancer, and immune regulation. His lab has made seminal contributions to understanding redox balance in metabolic health, T cell tolerance mechanisms, and central control of energy balance. These discoveries have significant translational potential, including intranasal therapies for obesity and genetically engineered CAR T cells for solid tumors. His recent publications span high-impact journals such as Journal of Clinical Investigation , Nature Communications , and Cell Metabolism , highlighting trends in redox signaling, immunometabolism, and therapeutic targeting of PTPs in cancer and metabolic disease. His work is frequently cited and has garnered attention from news outlets, social media, and the pharmaceutical industry. Melbourne University Postgraduate Scholarship (1990) C.J. Martin Fellowship, NHMRC (1995) AMRAD Post-Doctoral Award (1998) St. Vincent’s Hospital Research Week, Senior Investigator Prize (1999) Deans Award in Excellence in Research (2009) NHMRC Principal Research Fellowships (2010–2015, 2016–2020) Tony Tiganis actively supervises PhD students and leads multiple research projects funded by the National Breast Cancer Foundation and Cancer Council Victoria. He serves as an editor for FEBS Journal , Molecular & Cellular Biology , and Science Advances . His lab operates the Monash Metabolic Phenotyping Facility and collaborates with clinicians and chemists on translational programs. He is also a Scientific Advisory Board Member at DepYmed Inc. and a Consultant for Regeneron Pharmaceuticals. He leads a multidisciplinary team exploring the intersection of metabolism, immunity, and cancer, with ongoing projects investigating the impact of obesity on anti-tumor immunity and phosphatase roles in cancer pathogenesis.

• Cell Signalling
• Protein Tyrosine Phosphatases (PTPs)
• Obesity
• +12 more

Brett Gordon is an Associate Professor in Exercise Physiology and Head of Department for Rural Clinical Sciences at La Trobe University's Rural Health School in Bendigo, Australia. He is also an Accredited Exercise Physiologist (AEP) with over a decade of academic experience and nearly ten years of clinical practice. PhD from Royal Melbourne Institute of Technology University (2012) MAppSc (Exercise Rehabilitation) from Victoria University BAppSci (Human Movement) from Royal Melbourne Institute of Technology University Professor Gordon's research focuses on the role of exercise in managing chronic disease, particularly examining how exercise can be optimally assessed and prescribed for people with cardiometabolic health conditions. His work utilizes continuous glucose monitoring systems, accelerometers, and GPS monitors to study both healthy individuals and those with health conditions. Early in his career, he investigated exercise benefits for children with chronic fatigue syndrome before shifting focus to cardiometabolic health. Analysis of his recent publications reveals a strong emphasis on practical applications of exercise physiology in real-world settings, particularly in rural communities. His research spans walking football programs for older adults, optimal exercise dosing for cardiac rehabilitation, e-bike health benefits, military transition health issues, and telehealth applications for cardiac rehabilitation. A consistent theme across his work is addressing health disparities in rural populations. Member of Exercise and Sports Science Australia (ESSA), Research Committee Associate Editor for Frontiers in Sports and Active Living Member of Scientific Reports Editorial Board Member of American Association of Cardiovascular and Pulmonary Rehabilitation Professor Gordon has successfully supervised numerous students to completion, including 3 honours students (all H1), 1 master's student, and 5 doctoral students. He currently supervises 5 PhD candidates and 2 Master by Research candidates. His funded research includes projects on walking football for older adults and exercise demands in adolescent athletes. He maintains a broad collaborative network including institutions such as Auckland, Swinburne, Sheffield Hallam, Murdoch, RMIT, and Deakin universities, as well as Bendigo Health, The Austin Hospital, and the Baker IDI Heart and Diabetes Institute. His current research projects focus on prediabetes, diabetes, heart disease, hospital care, military transition, and resistance training, demonstrating his commitment to translating exercise science into practical health interventions for diverse populations.

• Exercise Physiology
• Diabetes
• Cardiovascular Disease
• +4 more

Dr. Vini Fernandes Cruzat is a Lecturer in Human Anatomy and Physiology at Southern Cross University’s Faculty of Health. He holds a PhD in Biomedical Science/Nutritional Biochemistry from the University of São Paulo and is a registered Nutritionist in Australia. His roles include Chair of the Queensland group of the Nutrition Society of Australia and Adjunct Senior Researcher at Griffith University. Academic Background: Bachelor in Exercise and Sport Science (Lutheran University of Brazil) Graduate Certificate in Learning and Teaching (Torrens University Australia) Master of Science in Nutritional Biochemistry (University of São Paulo) Dr. Cruzat’s research focuses on the metabolic, antioxidant, and anti-inflammatory effects of nutrient supplementation, particularly amino acids like glutamine, arginine, and leucine, as well as vitamin D and bioactive compounds from spent coffee grounds. He investigates cellular mechanisms in diabetes associated with obesity, emphasizing oxidative stress, insulin resistance, and heat shock protein pathways. His recent work explores the therapeutic potential of coffee byproducts and vitamin D in metabolic disorders. His publications over the past five years highlight a consistent focus on amino acid metabolism, oxidative stress in diabetes, and the intersection of nutrition/exercise with inflammation. Key trends include molecular studies of beta-cell dysfunction, clinical trials on supplementation, and applications of coffee compounds in functional food development. Dr. Cruzat has supervised 3 PhD, 6 MSc, and 5 Honours students across Australian and international institutions. He teaches human anatomy, physiology, and metabolic biochemistry and contributes to research networks in diabetes and exercise physiology.

• Physiology
• Metabolic Biochemistry
• Nutrition & Dietetics
• +8 more

Professor Jerry Greenfield is a distinguished Endocrinologist and Clinical Researcher at the University of New South Wales, holding multiple leadership positions including Head of Department of Endocrinology and Director of Diabetes Services at St Vincent's Hospital, as well as Head of St Vincent's Clinical Campus. His academic career spans decades of significant contributions to diabetes research and clinical practice. Greenfield completed his medical education at the University of New South Wales, graduating with Honours (Class 1) in 1995. He earned his PhD at the Garvan Institute (2001-2004) under the supervision of Professors D Chisholm, L Campbell, and K Samaras. His early career included an NHMRC Neil Hamilton Fairley Postdoctoral Research Fellowship at the University of Cambridge (2005-2006) where he worked with Prof Stephen O'Rahilly and Dr Sadaf Farooqi. His research interests focus on endocrinology with particular emphasis on type 1 and type 2 diabetes, obesity, metabolic disorders, insulin resistance, and cardiometabolic risk. Greenfield has pioneered work on SGLT2 inhibitors and their applications across various patient populations, including heart transplant recipients and those with specialized complications. His research bridges clinical practice with translational science, addressing critical gaps in diabetes management. Analysis of his recent publications (2023-2025) reveals a strong focus on cardiometabolic protection in diabetes, particularly examining SGLT2 inhibitors and GLP-1 receptor agonists for cardiovascular and renal protection in both type 1 and type 2 diabetes. His work spans clinical trials, population studies, and consensus guidelines development, with increasing attention to specialized populations including transplant recipients and those with monogenic diabetes. NHMRC Neil Hamilton Fairley Postdoctoral Research Fellowship Editorial Board member, Clinical Obesity Executive Council Member, Australian Diabetes Society Professor Greenfield leads significant research initiatives examining the role of novel diabetes medications in cardiometabolic protection. His work has secured substantial research funding through NHMRC and other competitive grants. He actively collaborates with multidisciplinary teams across endocrinology, cardiology, and transplant medicine to advance diabetes care. His leadership extends to developing national consensus statements on genetic testing for monogenic diabetes and improving management of diabetic ketoacidosis across Australia. Greenfield maintains strong affiliations with the Garvan Institute of Medical Research and St Vincent's Hospital, where his research team investigates metabolic pathways, insulin resistance mechanisms, and clinical applications of novel diabetes therapies. His work with the Australian Diabetes Society has significantly influenced clinical practice guidelines and research directions in the field.

• Endocrinology
• Diabetes Research
• Type 1 Diabetes
• +6 more

Brendan Dyett is a Research Fellow at RMIT University, supported by an Australian Research Council Discovery Early Career Award. His research focuses on nanoscale dynamics at interfaces using microscopy and scattering techniques. He investigates lipid nanoparticle-cell interactions, non-wetting thin films, and surface nanobubbles/droplets, with applications in overcoming biological barriers for therapeutic delivery. He is affiliated with RMIT’s Research & Innovation Portfolio and teaches courses such as CHEM1015 (Environmental Chemical Issues) and ONPS2186 (Applied Science Project). His research interests span colloid and surface chemistry, nanomedicine, and modeling/simulation. He contributes to UN Sustainable Development Goals 3 (Good Health) and 10 (Reduced Inequalities). Recent projects include developing lipid nanocarriers for mRNA delivery and antimicrobial peptide encapsulation. Awards: Australian Research Council Discovery Early Career Award Grants: ARC-funded research on lipid nanoparticle mechanistic studies Collaborations: Industry projects and media inquiries welcomed His work bridges fundamental materials science with biomedical applications, emphasizing nanostructured systems for drug delivery and disease treatment.

• Colloid and Surface Chemistry
• Nanomedicine
• Therapeutic Delivery
• +3 more

Jason Chami is a Clinical Associate Lecturer at the Central Clinical School within the Faculty of Medicine and Health at the University of Sydney. His academic appointment focuses on clinical teaching and research in cardiology and medical informatics, with affiliations spanning the Sydney Medical School and Central Clinical School. His research interests center on cardiology, particularly congenital heart disease complexity stratification, registry systems, and medical coding accuracy. He also investigates ophthalmology (glaucoma devices), metabolism (cardiometabolic biomarkers), and neuroscience (pain pathways). His work integrates clinical data analysis with informatics approaches to improve diagnostic precision and patient outcomes. Analysis of his 2020-2025 publications reveals dominant themes in congenital heart disease research, including algorithmic risk stratification, registry optimization, and coding error reduction. Secondary streams include ophthalmology (PreserFlo MicroShunt safety studies), metabolism (Slc16a13 gene impacts), and neuroscience (neuroreceptor changes in pain models), demonstrating cross-disciplinary clinical research methodology.

• Cardiology
• Congenital Heart Disease
• Medical Informatics
• +4 more

Dr Helena Qin is a Senior Research Fellow at Monash University's Monash Institute of Pharmaceutical Science (Drug Discovery Biology Theme) and holds adjunct roles at the Baker Heart and Diabetes Institute and the University of Melbourne. She leads the National Heart Foundation Future Fellow laboratory, focusing on developing novel therapies for cardiovascular diseases through translational pharmacology and GPCR biology. Educated at the University of Melbourne, she earned a B.Biomed, PhD in Pharmacology, and First Class Honours in Medicinal Chemistry. Her research emphasizes formyl peptide receptors (FPRs) and their role in inflammation resolution, with nearly 40 publications in top journals. Key achievements include identifying FPRs' therapeutic potential against cardiovascular diseases and pioneering biased agonist drug design. Awarded prestigious fellowships (National Heart Foundation, JDRF, Baker Institute), her work addresses UN SDG 3 (Good Health) and 9 (Industry/Innovation). Major grants include NHMRC, National Heart Foundation, and Diabetes Australia funding. She actively mentors students and leads projects on GPCR-targeted therapeutics and pro-resolving medicines for cardiovascular and diabetic vascular conditions.

• Translational Pharmacology
• Cardiovascular Disease
• GPCR Biology
• +3 more

Dr. Jennifer Gunter is a Senior Research Fellow at Queensland University of Technology (QUT), affiliated with the Faculty of Health and the School of Biomedical Sciences. Her research focuses on metabolic plasticity in cancer cells, particularly prostate cancer, and the interplay between metabolic disorders and cancer progression. She completed her PhD in 2005 at the University of Oxford, studying lipid metabolism in type-2 diabetes, and has since held postdoctoral positions at the University of Queensland and QUT. Her work integrates metabolomics, cell biology, and clinical translation to identify therapeutic targets. Key areas include insulin resistance, androgen receptor signaling, and drug discovery. Dr. Gunter has secured over $7.9 million in competitive grants and published over 20 peer-reviewed articles, reviews, and book chapters. Her team explores adaptive metabolic pathways in response to therapies like androgen deprivation and biguanides. Dr. Gunter collaborates on projects involving biomaterials (e.g., hydrogel models) and nanoparticle drug delivery. Her research highlights the importance of metabolic reprogramming in treatment resistance and metastasis. She also investigates the role of leptin and cytokines in tumor progression. Future work aims to translate findings into personalized therapies for urological cancers.

• Cancer Metabolism
• Prostate Cancer
• Insulin Resistance
• +6 more

Christopher Porter is the Sir John Monash Distinguished Professor and Director of the Monash Institute of Pharmaceutical Sciences (MIPS) at Monash University. He holds fellowships with the American Association of Pharmaceutical Scientists and the Royal Australian Chemical Institute. His research focuses on drug delivery systems, lymphatic transport, and nanomedicines, with significant contributions to lipid-based formulations and dendrimer technologies. Key achievements include the Glyph® lymphatic targeting platform (Phase 2 clinical trial) and the DEP® dendrimer system (Phase 2 clinical trial). Education: Undergraduate and graduate studies at the University of Nottingham. Key Awards: Clarivate Highly Cited Researcher (2015–2024), APSA Medal (2017), Honorary Doctorate (Uppsala University, 2018). Research interests span oral bioavailability enhancement, lipid-modified drug systems, and translational drug delivery. His work has generated over $30M in funding and 15+ patent families. Notable collaborations include PureTech Health/Seaport Therapeutics and Starpharma.

• Oral Drug Delivery
• Bioavailability Enhancement
• Lymphatic Drug Transport
• +5 more

Professor David James holds the Leonard P. Ullmann Chair of Metabolic Systems Biology at the Charles Perkins Centre, University of Sydney. He is a Professor in both the School of Life and Environmental Sciences and the School of Medicine. His research focuses on metabolic diseases, particularly Type 2 diabetes, leveraging systems biology approaches to dissect metabolic homeostasis. He leads the James Lab and collaborates with the Metabolic Cybernetics team. Key research interests include understanding how genetics and environment influence metabolic disorders, with a focus on insulin resistance, adipocyte biology, and omics technologies. His lab employs proteomics, metabolomics, and computational biology to unravel disease mechanisms. Professor James has secured grants totaling over $15 million, including the NHMRC Ideas Grant for studies on mitochondrial defects and cardiometabolic disease. He leads multidisciplinary teams at the Charles Perkins Centre, fostering collaborations in imaging, computational biology, and molecular genetics. Awards include the ARC Laureate Fellowship. His lab trains PhD candidates in metabolic research, with current advisees including Alexis Diaz, Harry Cutler, and Yiju Zhang. Research outputs span metabolic pathways, genetic diversity, and drug development for metabolic diseases.

• Metabolic Systems Biology
• Type 2 Diabetes
• Metabolic Homeostasis
• +4 more